Mustang Bio to Participate in Three March 2022 Investor Conferences

On March 10, 2022 Mustang Bio, Inc. ("Mustang") (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors and rare genetic diseases, reported that Manuel Litchman, M.D., President and Chief Executive Officer, will participate in three virtual investor conferences in March 2022 (Press release, Mustang Bio, MAR 10, 2022, View Source(%E2%80%9CMustang%E2%80%9D)%20(NASDAQ,President%20and%20Chief%20Executive%20Officer%2C [SID1234609914]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Details of the events are as follows:

Oppenheimer’s 32nd Annual Virtual Healthcare Conference: The company will participate in a fireside chat on Tuesday, March 15, 2022, at 4:00 p.m. ET and will participate in one-on-one meetings during the conference. A webcast of the company’s fireside chat will be available on the News & Events page of the Investor Relations section of Mustang’s website, www.mustangbio.com, for approximately 30 days after the meeting.
H.C. Wainwright’s Gene Therapy and Gene Editing Conference: The company’s presentation will be available for on-demand viewing on Mustang’s website beginning Wednesday, March 30, 2022, at 7:00 a.m. ET and will remain available on the News & Events page of the Investor Relations section of Mustang’s website, www.mustangbio.com, for approximately 30 days after the meeting. The company will also participate in one-on-one meetings during the conference.
Cantor Fitzgerald’s Rare Orphan Disease Summit: The company will participate in a panel presentation on Wednesday, March 30, 2022, at 4:00 p.m. ET, titled, "Cell Therapy: How the Definition Has Expanded With Time, and the Potential Applications For Rare Diseases."